Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry.

[1]  B. Ogunjimi,et al.  Development and Implementation of the AIDA International Registry for Patients With Still's Disease , 2022, Frontiers in Medicine.

[2]  A. Doria,et al.  Progress in Biological Therapies for Adult-Onset Still’s Disease , 2022, Biologics : targets & therapy.

[3]  C. Masciocchi,et al.  The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile , 2021, Scientific Reports.

[4]  P. Sfikakis,et al.  Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. , 2020, Seminars in arthritis and rheumatism.

[5]  M. Özgen,et al.  Adult‐onset still’s disease and treatment results with tocilizumab , 2020, International journal of clinical practice.

[6]  A. Vitale,et al.  Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease , 2020, Mediators of inflammation.

[7]  K. Uehara,et al.  Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still’s disease with a previous successful tocilizumab treatment , 2020, Modern rheumatology case reports.

[8]  B. Anić,et al.  Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review , 2020, Rheumatology International.

[9]  R. De Giorgio,et al.  The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies , 2020, Therapeutic advances in musculoskeletal disease.

[10]  C. Campochiaro,et al.  The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. , 2020, Clinical and experimental rheumatology.

[11]  T. Barnetche,et al.  Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy , 2019, Arthritis Research & Therapy.

[12]  R. Cimaz,et al.  Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis , 2019, Front. Pharmacol..

[13]  Yoshiya Tanaka,et al.  Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial , 2018, Annals of the rheumatic diseases.

[14]  E. Feist,et al.  Mechanisms, biomarkers and targets for adult-onset Still’s disease , 2018, Nature Reviews Rheumatology.

[15]  Y. Shoenfeld,et al.  A comprehensive review on adult onset Still's disease. , 2018, Journal of autoimmunity.

[16]  D. Foell,et al.  IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry) , 2018, Pediatric Rheumatology.

[17]  Jiajia Yang,et al.  Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: A meta-analysis , 2018, Modern rheumatology.

[18]  Kazuhiko Yamamoto,et al.  Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease , 2017, Modern rheumatology.

[19]  M. Kawano,et al.  Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. , 2016, Clinical immunology.

[20]  D. Solmaz,et al.  Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. , 2016, Journal of autoimmunity.

[21]  T. Kano,et al.  Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease , 2016, Modern rheumatology.

[22]  P. Sève,et al.  Adult-onset Still's disease. , 2014, Autoimmunity reviews.

[23]  S. Castañeda,et al.  Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients , 2014, Arthritis & rheumatology.

[24]  P. Nigrovic.  Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis? , 2014, Arthritis & rheumatology.

[25]  J. Ablin,et al.  Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience , 2014, The Journal of Rheumatology.

[26]  R. Giacomelli,et al.  Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series , 2013, Clinical Rheumatology.

[27]  C. Wouters,et al.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[28]  H. Kautiainen,et al.  Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study , 2012, The Journal of Rheumatology.

[29]  A. Tzioufas,et al.  Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study , 2011, Arthritis research & therapy.

[30]  A. Mimori,et al.  Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome , 2011, Modern rheumatology.

[31]  J. Sibilia,et al.  Tocilizumab in refractory adult Still's disease , 2011, Arthritis care & research.

[32]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[33]  T. Hsieh,et al.  Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. , 2004, The Journal of rheumatology.

[34]  J. Volanakis,et al.  Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. , 1998, Journal of immunology.

[35]  M. Akizuki,et al.  Preliminary criteria for classification of adult Still's disease. , 1992, The Journal of rheumatology.

[36]  J. Esdaile,et al.  Adult Still's Disease: Manifestations, Disease Course, and Outcome in 62 Patients , 1991, Medicine.